<DOC>
	<DOC>NCT00977600</DOC>
	<brief_summary>To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.</brief_summary>
	<brief_title>A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)</brief_title>
	<detailed_description>A randomized, open-label, four-treatment, four-period crossover study in which healthy male subjects received a single dose of each of the following four treatments on four separate dosing days, 7 days apart: - Oral sodium phenylbutyrate (Buphenyl®) equivalent to 3 g/m2 of 4-phenylbutyric acid (PBA) per dose - Oral GT4P-F mole equivalents to 3 g/m2 of PBA per dose - Oral GT4P-API mole equivalents to 3 g/m2 of PBA per dose - Intravenous 10% sodium phenylacetate plus 10% sodium benzoate (Ammonul®) 2.75 g/m2</detailed_description>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<mesh_term>Phenylacetic acid</mesh_term>
	<mesh_term>Sodium Benzoate</mesh_term>
	<criteria>Subjects were required to fulfill the following criteria in order to participate in the study: Males aged 18 to 45 years of age Ability to provide written, informed consent before any studyrelated procedures, and ability, in the opinion of the investigator, to comply with all the requirements of the study Subjects who were in good health as determined by a medical history, physical examination, serum chemistry, hematology, urinalysis, 12 lead ECG, and vital signs Weight within the range of 60120 kg Subjects who fulfilled any of the following criteria were excluded from the study: Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurologic, immunologic, or psychiatric disorder(s), as determined by the investigator Clinically significant abnormal laboratory values (as determined by the investigator) Significant illness within 14 days prior to screening Any disorder that might significantly interfere with the absorption, distribution, metabolism, or excretion of any drug Use of any prescription medication within 14 days prior to screening Use of dietary supplements, herbal medicines, vitamins, or overthecounter medication(s) (with the exception of acetaminophen ≤ 500 mg/day) within 10 days prior to first dosing Positive drugs of abuse urine test at screening or predose day (cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids, methadone) Positive alcohol breath test at screening or predose day Donation or loss of blood (500 ml or more) within 30 days prior to first dosing, or during the study Donation or loss of plasma within 7 days prior to first dosing, or during the study History of or current hepatitis or carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (antiHC) History of acquired immunodeficiency syndrome (AIDS) or determined HIV positive at screening Use of any investigational drug within 12 weeks prior to first dosing Known hypersensitivity to sodium phenylbutyrate or similar drugs Previous exposure to sodium phenylbutyrate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ammonul</keyword>
	<keyword>Sodium phenylacetate</keyword>
	<keyword>sodium benzoate</keyword>
	<keyword>Buphenyl</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>HPN-100</keyword>
	<keyword>GT4P</keyword>
	<keyword>Glyceryl tri-(4-phenylbutyrate)</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>